JP2008516922A - ヒスタミン受容体リガンドとしてのピロリジン誘導体 - Google Patents
ヒスタミン受容体リガンドとしてのピロリジン誘導体 Download PDFInfo
- Publication number
- JP2008516922A JP2008516922A JP2007536122A JP2007536122A JP2008516922A JP 2008516922 A JP2008516922 A JP 2008516922A JP 2007536122 A JP2007536122 A JP 2007536122A JP 2007536122 A JP2007536122 A JP 2007536122A JP 2008516922 A JP2008516922 A JP 2008516922A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- aryl
- heteroaryl
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(CC1)N(*)CC(C)(*)CN1C(C1CNCC(C)(C)C1)=O Chemical compound CC(CC1)N(*)CC(C)(*)CN1C(C1CNCC(C)(C)C1)=O 0.000 description 3
- QBJWLJXVGOFHFX-SFHVURJKSA-N CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1-c1nc(C)n[o]1)=O Chemical compound CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1-c1nc(C)n[o]1)=O QBJWLJXVGOFHFX-SFHVURJKSA-N 0.000 description 1
- YOJAJLNNCCLRHB-AWEZNQCLSA-N CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c1cnc(C(F)(F)F)cc1)=O Chemical compound CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c1cnc(C(F)(F)F)cc1)=O YOJAJLNNCCLRHB-AWEZNQCLSA-N 0.000 description 1
- VJZWGYSVNQTUQK-ZDUSSCGKSA-N CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c1cnc(C(F)(F)F)nc1)=O Chemical compound CC(C)N(CC1)CCN1C([C@@H](CC1)CN1c1cnc(C(F)(F)F)nc1)=O VJZWGYSVNQTUQK-ZDUSSCGKSA-N 0.000 description 1
- UPMCRBZHCZHCPO-IBGZPJMESA-N CC(C)N(CCC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1C(C)=O)=O Chemical compound CC(C)N(CCC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1C(C)=O)=O UPMCRBZHCZHCPO-IBGZPJMESA-N 0.000 description 1
- PKXKZAADEFDOIS-KRWDZBQOSA-N CCN(CC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1-c1nc(C)n[o]1)=O Chemical compound CCN(CC1)CCN1C([C@@H](CC1)CN1c(cc1)ccc1-c1nc(C)n[o]1)=O PKXKZAADEFDOIS-KRWDZBQOSA-N 0.000 description 1
- GYAQMQBOMPCTPH-LURJTMIESA-N C[C@@H](C1)NCCN1C=O Chemical compound C[C@@H](C1)NCCN1C=O GYAQMQBOMPCTPH-LURJTMIESA-N 0.000 description 1
- LXKMZMNNAKJQFD-IBGZPJMESA-N Cc1n[o]c(-c(cc2)ccc2N(CC2)C[C@H]2C(N2CCN(CC3CC3)CC2)=O)n1 Chemical compound Cc1n[o]c(-c(cc2)ccc2N(CC2)C[C@H]2C(N2CCN(CC3CC3)CC2)=O)n1 LXKMZMNNAKJQFD-IBGZPJMESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0423005A GB0423005D0 (en) | 2004-10-15 | 2004-10-15 | Novel compounds |
| GB0508441A GB0508441D0 (en) | 2004-10-15 | 2005-04-26 | Novel compounds |
| PCT/EP2005/011371 WO2006040192A1 (en) | 2004-10-15 | 2005-10-13 | Pyrrolidine derivatives as histamine receptors ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516922A true JP2008516922A (ja) | 2008-05-22 |
| JP2008516922A5 JP2008516922A5 (enExample) | 2008-11-27 |
Family
ID=35583486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536122A Withdrawn JP2008516922A (ja) | 2004-10-15 | 2005-10-13 | ヒスタミン受容体リガンドとしてのピロリジン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080045506A1 (enExample) |
| EP (1) | EP1802307B1 (enExample) |
| JP (1) | JP2008516922A (enExample) |
| AR (1) | AR051391A1 (enExample) |
| AT (1) | ATE387202T1 (enExample) |
| DE (1) | DE602005005080T2 (enExample) |
| DK (1) | DK1802307T3 (enExample) |
| ES (1) | ES2303280T3 (enExample) |
| HR (1) | HRP20080227T3 (enExample) |
| PL (1) | PL1802307T3 (enExample) |
| PT (1) | PT1802307E (enExample) |
| SI (1) | SI1802307T1 (enExample) |
| WO (1) | WO2006040192A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| CN101472887A (zh) | 2006-06-23 | 2009-07-01 | 艾博特公司 | 作为组胺h3受体调节物的环丙胺衍生物 |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| BRPI0815591B8 (pt) | 2007-08-22 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e, uso de um composto. |
| WO2009030716A1 (en) | 2007-09-06 | 2009-03-12 | Glaxo Group Limited | Piperazine derivative having affinity for the histamine h3 receptor |
| ES2428716T3 (es) | 2008-02-22 | 2013-11-11 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide |
| CA2721303C (en) | 2008-05-08 | 2016-06-28 | Evotec Ag | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
| US8236792B2 (en) | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| JP5530438B2 (ja) * | 2008-08-06 | 2014-06-25 | ファイザー・リミテッド | Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物 |
| JP5502089B2 (ja) | 2008-10-09 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
| WO2010052199A1 (en) | 2008-11-10 | 2010-05-14 | F. Hoffmann-La Roche Ag | Heterocyclic gamma secretase modulators |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| US8912176B2 (en) | 2009-02-02 | 2014-12-16 | Evotec Ag | Azetidines as histamine H3 receptor antagonists |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2011016559A1 (ja) * | 2009-08-07 | 2011-02-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| AU2011218492B2 (en) | 2010-02-18 | 2014-11-13 | Astrazeneca Ab | New crystalline form of a cyclopropyl benzamide derivative |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| AU2023247609A1 (en) * | 2022-03-31 | 2024-10-17 | Bebetter Med Inc. | 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128428A0 (en) * | 1996-08-14 | 2000-01-31 | Zeneca Ltd | Substituted pyrimidine derivatives and their pharmaceutical use |
| DE10034338C2 (de) * | 2000-07-14 | 2002-06-20 | Forschungszentrum Juelich Gmbh | Mehrpoliges kaskadierendes Quardrupel-Bandpaßfilter auf der Basis dielektrischer Dual-Mode-Resonatoren |
| JPWO2003062234A1 (ja) * | 2002-01-23 | 2005-05-19 | 山之内製薬株式会社 | キノキサリン化合物 |
| JP2006505590A (ja) * | 2002-10-23 | 2006-02-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン |
| AU2004238447C1 (en) * | 2003-04-23 | 2009-06-11 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
-
2005
- 2005-10-13 PL PL05802453T patent/PL1802307T3/pl unknown
- 2005-10-13 JP JP2007536122A patent/JP2008516922A/ja not_active Withdrawn
- 2005-10-13 US US11/576,968 patent/US20080045506A1/en not_active Abandoned
- 2005-10-13 DE DE602005005080T patent/DE602005005080T2/de not_active Expired - Lifetime
- 2005-10-13 HR HR20080227T patent/HRP20080227T3/xx unknown
- 2005-10-13 EP EP05802453A patent/EP1802307B1/en not_active Expired - Lifetime
- 2005-10-13 WO PCT/EP2005/011371 patent/WO2006040192A1/en not_active Ceased
- 2005-10-13 PT PT05802453T patent/PT1802307E/pt unknown
- 2005-10-13 ES ES05802453T patent/ES2303280T3/es not_active Expired - Lifetime
- 2005-10-13 DK DK05802453T patent/DK1802307T3/da active
- 2005-10-13 SI SI200530241T patent/SI1802307T1/sl unknown
- 2005-10-13 AT AT05802453T patent/ATE387202T1/de not_active IP Right Cessation
- 2005-10-13 AR ARP050104299A patent/AR051391A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1802307T3 (pl) | 2008-07-31 |
| ATE387202T1 (de) | 2008-03-15 |
| PT1802307E (pt) | 2008-06-06 |
| WO2006040192A1 (en) | 2006-04-20 |
| EP1802307B1 (en) | 2008-02-27 |
| DK1802307T3 (da) | 2008-06-30 |
| ES2303280T3 (es) | 2008-08-01 |
| HRP20080227T3 (hr) | 2008-06-30 |
| SI1802307T1 (sl) | 2008-08-31 |
| US20080045506A1 (en) | 2008-02-21 |
| AR051391A1 (es) | 2007-01-10 |
| DE602005005080D1 (de) | 2008-04-10 |
| DE602005005080T2 (de) | 2009-02-26 |
| EP1802307A1 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516922A (ja) | ヒスタミン受容体リガンドとしてのピロリジン誘導体 | |
| JP4824567B2 (ja) | 新規化合物 | |
| KR102082331B1 (ko) | Cot 조정제로서의 6-아미노-퀴놀린-3-카르보니트릴 | |
| KR20050121268A (ko) | 피페라진 유도체 및 신경적 및 정신적 질병의 치료를 위한그의 용도 | |
| JP2007514690A (ja) | ヒスタミンｈ３アンタゴニストとしてのベンズアゼピン誘導体 | |
| JP2008509955A (ja) | ヒスタミンｈ３受容体のアンタゴニストおよび／または逆アゴニストとしてのテトラヒドロベンズアゼピン | |
| US7638631B2 (en) | Methylene dipiperidine derivatives | |
| US20060247227A1 (en) | Substituted piperidines as histamine h3 receptor ligands | |
| JP2008502644A (ja) | ヒスタミンｈ３アンタゴニストとしての３−シクロアルキルベンズアゼピン | |
| JP5145218B2 (ja) | ヒスタミンｈ３アンタゴニストとしてのピラゾロ［３，４−ｄ］アゼピン誘導体 | |
| KR20070091007A (ko) | 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도 | |
| US20080009479A1 (en) | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | |
| KR20070113225A (ko) | 히스타민 ｈ３ 수용체에 대해 친화성을 갖는 융합된 티아졸유도체 | |
| CN101115721A (zh) | 茚基衍生物和它们在治疗神经疾病中的用途 | |
| WO2004056821A2 (en) | Quinolizidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081010 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081010 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20101210 |